Last reviewed · How we verify
SRAM study_Postate Cancer
This is a phase 2 randomized study for High risk localized prostate cancer (T3 to T4 disease and/or PSA \> 20 and/or Gleason score ≥ 8) without evidence of distant and nodal metastasis. Patient will be randomized to:Arm 1 * Conventional IMRT RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes). * 38 fractions of daily treatment, Monday to Friday or Arm 2 SBRT * RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) * 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy (detail as below)
Details
| Lead sponsor | CCTU |
|---|---|
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 120 |
| Start date | Wed May 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Dec 31 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Advanced Prostate Cancer
Interventions
- Conventional IMRT
- SBRT
Countries
Hong Kong